Provided by Tiger Fintech (Singapore) Pte. Ltd.

CINGULATE INC.

4.32
+0.02000.47%
Post-market: 4.320.00000.00%16:42 EDT
Volume:39.05K
Turnover:170.36K
Market Cap:16.28M
PE:-0.42
High:4.41
Open:4.30
Low:4.25
Close:4.30
Loading ...

Company Profile

Company Name:
CINGULATE INC.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
13
Office Location:
1901 West 47th Place,Kansas City,Kansas,United States
Zip Code:
66205
Fax:
- -
Introduction:
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Directors

Name
Position
Shane J. Schaffer
Chief Executive Officer and Chairman of the Board
Curt Medeiros
Director
Gregg Givens
Director
Jeff Conroy
Director
Jeff Hargroves
Director
Patrick Gallagher
Director
Peter J. Werth
Director

Shareholders

Name
Position
Shane J. Schaffer
Chief Executive Officer and Chairman of the Board
Laurie A. Myers
Executive Vice President and Chief Operating Officer
Louis G. Van Horn
Executive Vice President and Chief Financial Officer
Craig S. Gilgallon
Executive Vice President and General Counsel
Matthew Brams
Executive Vice President and Chief Medical Officer
Raul R. Silva
Executive Vice President and Chief Science Officer